Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226,220,429
-
Total 13F shares
-
54,998,315
-
Share change
-
+54,998,315
-
Total reported value
-
$1,469,849,010
-
Price per share
-
$26.93
-
Number of holders
-
79
-
Value change
-
+$1,469,848,998
-
Number of buys
-
78
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2018
As of 31 Dec 2018,
Allogene Therapeutics, Inc. - Common Stock (ALLO) was held by
79 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,998,315 shares.
The largest 10 holders included
TPG Group Holdings (SBS) Advisors, Inc., FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, Capital Research Global Investors, Capital World Investors, BlackRock Inc., Vanguard Group Inc, Capital International Investors, PERCEPTIVE ADVISORS LLC, and ALLIANCEBERNSTEIN L.P..
This page lists
78
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.